Format

Send to

Choose Destination
Future Oncol. 2012 Apr;8(4):403-14. doi: 10.2217/fon.12.22.

Bevacizumab and breast cancer: what does the future hold?

Author information

1
Department of Surgery, University of Connecticut Health Center, Farmington, CT 06030, USA.

Abstract

Breast cancer is a major health concern for many women, but despite the current standard therapies, many women still die of metastatic disease. Angiogenesis has been evaluated as a possible target for therapy and bevacizumab (Avastin(®), Genentech/Roche, CA, USA), a monoclonal antibody against VEGF-A, has been developed to target this. Current clinical trials utilizing bevacizumab have shown an increase in progression-free survival, but this has not translated to an increase in overall survival in breast cancer patients. In this article, we summarize the currently published trials utilizing bevacizumab in the treatment of breast cancer and describe various methods of measuring angiogenesis in vitro and in vivo. We also describe the related process of lymphangiogenesis, as this may contribute to the mechanism of cancer progression and may be a potential target for therapy in the future. Understanding these processes may help us develop new treatments for breast cancer.

PMID:
22515444
PMCID:
PMC3464486
DOI:
10.2217/fon.12.22
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Atypon Icon for PubMed Central
Loading ...
Support Center